# SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure

> **NCT06955260** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Subodh Verma** · enrollment: 410 (estimated)

## Conditions studied

- Congenital Heart Disease

## Interventions

- **DRUG:** Empagliflozin 10 mg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06955260
- **Lead sponsor:** Subodh Verma
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-05
- **Primary completion:** 2027-12
- **Final completion:** 2028-03
- **Target enrollment:** 410 (ESTIMATED)
- **Last updated:** 2025-05-02

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06955260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06955260, "SGLT2 Inhibition With Empagliflozin in Fontan Circulatory Failure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06955260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*